Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. SEOM-SOGUG clinical guideline for urothelial cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
   Guideline
2. SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
   Guideline
3. Potential utility of ADNP in circulating tumor cells as biomarker for prognostics in non-muscle-invasive bladder cancer.Scientific reports · 2024
   Article
4. Adequate Pelvic Lymph Node Dissection in Radical Cystectomy in the Era of Neoadjuvant Chemotherapy: A Meta-Analysis and Systematic Review.Cancers · 2023
   Review
5. The Influence of Lymph Node Count on Oncological Outcome of Radical Cystectomy in Chemotherapy Pre-Treated and Chemotherapy-Naïve Patients with Muscle Invasive Bladder Cancer.Journal of clinical medicine · 2021
   Article
6. Neoadjuvant vascular-targeted photodynamic therapy improves survival and reduces recurrence and progression in a mouse model of urothelial cancer.Scientific reports · 2021
   Article
7. Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer.Investigative and clinical urology · 2020
   Article
8. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo.Oncotarget · 2016
   Article
9. BcCluster: A Bladder Cancer Database at the Molecular Level.Bladder cancer (Amsterdam, Netherlands) · 2016
   Article
10. [Pharmaceutical treatment of advanced urinary bladder cancer: new developments in 2014].Der Urologe. Ausg. A · 2014
    Review

Corrections and comments

• Commented on by
  Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.2014
• Comment on
  Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.2014
• Comment on
  Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as